Dermot Mark Durcan

Director

Dermot Mark Durcan (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Cencora, Inc. (COR). Across 2 priced purchase filings, the average 21-session return was +8.2% from execution and +8.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of COR (4,000 sh × $274.19, as filed), executed Jun 18.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+8.2%

avg across 2 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+8.9%

same 2 filings, from disclosure

Filings, ttm

2 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$2.2M

shares × price, as filed

Last traded

Jun 18

Filed Jun 22

Median ADV $573.9M across their filed names

Open performance→

Volume by month

Buys $2.2M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names

COR

Cencora, Inc. COR · 2 buys · 0 sells 2 filings

Recent filings

CORPURCHASE Cencora, Inc. View filing → $1.1M
4,000 sh × $274.19
Exec Jun 18
Filed Jun 22 · 4:05 PM ET CORPURCHASE Cencora, Inc. View filing → $1.1M
4,000 sh × $266.26
Exec May 28
Filed May 28 · 4:23 PM ET